Industry

The conversation around healthcare affordability continues to evolve, with a renewed focus on price transparency. On Tuesday, President Donald Trump signed an executive order reinforcing rules established during his first term that mandate greater transparency in healthcare pricing. This order directs regulators to update enforcement policies, ensuring that hospitals and payers comply with transparency requirements. […]

In today’s healthcare landscape, medication cost is under increasing scrutiny. Regulatory bodies and public demand for transparency are putting pricing pressures on pharmaceutical companies—especially for high-demand medications. As pricing regulations evolve, healthcare providers and pharmacies need reliable partners to ensure consistent access to affordable pharmaceutical solutions. The Growing Focus on Pricing With healthcare costs on

Artificial intelligence (AI) is transforming healthcare, offering new possibilities for improving patient outcomes, streamlining operations, and enabling data-driven decision-making. However, as adoption accelerates, the importance of responsible AI practices has come to the forefront. Leading healthcare organizations are prioritizing measurable impact, ethical use, and workforce upskilling. These efforts ensure AI’s transformative power is leveraged responsibly

In a significant move, the FDA has proposed the removal of decongestants from many over-the-counter (OTC) cold and allergy medications. This decision addresses concerns about their effectiveness. The FDA found insufficient evidence to support their ability to provide relief. Why is the FDA Proposing This Change? The FDA’s proposed action follows a comprehensive review of

In recent years, U.S. medication makers have begun reducing their reliance on Chinese suppliers for key medication components. This shift affects every part of the pharmaceutical ecosystem, representing a significant change in how medications are sourced and produced. Why Are Pharmaceutical Companies Rethinking Their Supply Chains? China has long been a leading supplier of Active

A tragic chapter in public health came to a close as a pharmacist was sentenced to up to 15 years in prison for his role in a deadly meningitis outbreak linked to contaminated medications. The outbreak, which occurred in 2012, resulted in more than 100 deaths and sickened hundreds of patients across multiple states. The

As the flu season picks up in the U.S., recent data from the CDC indicates this year’s flu shot effectiveness may be lower than anticipated. With early reports suggesting a downward trend in protection, healthcare providers are now facing questions about how to best safeguard against the influenza virus, especially for vulnerable populations. Fluctuations in Flu

The pharmaceutical industry has been facing significant supply chain disruptions in recent years, with rising costs of APIs (active pharmaceutical ingredients) becoming a major concern. These disruptions are primarily caused by several factors, including natural disasters in the U.S., port congestion, and global instability. For companies like UDose™ that rely on a consistent supply of